Home » News » Drug Sponsors » Galen acquires Synera topical patch

Galen acquires Synera topical patch

Friday, July 12, 2013

Galen, a Northern Ireland-based pharmaceutical company, has acquired Synera (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, a wholly-owned subsidiary of Nuvo Research. Synera is indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy of skin lesions. Galen U.S., a wholly owned subsidiary of Galen, will market and sell Synera in the U.S.

“Synera addresses a need to provide local dermal analgesia, particularly in children three years or older,” said Andrew Shales, Galen general manager. “Hospitalized patients are routinely subjected to multiple superficial venous access procedures such as IV infusions and blood draws. We entered the U.S. market in 2012 and this acquisition provides us with the opportunity to offer innovative technology for patients needing local dermal analgesia.”  

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!